Neos Therapeutics is an oral drug delivery company developing controlled time-release technologies. The Company develops, manufactures, and commercializes innovative extended-release products using its proprietary extended-release drug delivery and orally disintegrating tablet (ODT) technology platforms. 

Neos Therapeutics has two FDA-approved products for the treatment of ADHD and both utilize its extended-release ODT technology.

The Company's growing ADHD Product Portfolio puts Neos in a unique position to meet the different needs of patients that struggle with ADHD.

TypePublic
HQGrand Prairie, US
Founded2008
Size (employees)134 (est)
Websiteneostx.com
Neos Therapeutics was founded in 2008 and is headquartered in Grand Prairie, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Neos Therapeutics Office Locations

Neos Therapeutics has offices in Grand Prairie and Blue Bell
Grand Prairie, US (HQ)
2940 N. Highway 360
Blue Bell, US
130 1787 Sentry Pkwy W
Show all (2)
Report incorrect company information

Neos Therapeutics Financials and Metrics

Neos Therapeutics Revenue

Embed Graph
Neos Therapeutics's revenue was reported to be $9.15 m in FY, 2016 which is a 141.4% increase from the previous period.
USD

Net income (Q2, 2018)

(29.6m)

EBIT (Q2, 2018)

(25.8m)

Market capitalization (18-Oct-2018)

119.9m

Closing stock price (18-Oct-2018)

4.0

Cash (30-Jun-2018)

18.3m

EV

161.5m
Neos Therapeutics's current market capitalization is $119.9 m.
Annual
USDFY, 2015FY, 2016

Revenue

3.8m9.2m

Revenue growth, %

141%

Cost of goods sold

5.5m11.4m

Gross profit

(1.8m)(2.3m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

1.5m221.0k

Cost of goods sold

2.3m1.7m2.3m4.6m2.6m2.4m5.2m12.2m

General and administrative expense

1.7m2.1m3.6m3.5m3.1m3.5m3.3m3.3m7.1m

R&D expense

2.1m2.7m2.3m4.3m2.9m1.7m3.7m1.7m4.1m
Annual
USDFY, 2015FY, 2016

Cash

90.8m24.4m

Accounts Receivable

1.2m

Inventories

2.5m5.8m

Current Assets

98.2m55.3m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

25.6m102.9m42.4m41.9m43.5m43.7m57.4m43.4m24.8m18.3m

Inventories

1.7m2.7m2.5m4.4m5.7m5.6m6.1m10.0m13.4m12.7m

Current Assets

29.7m106.4m93.1m91.9m72.0m74.7m93.1m87.9m73.1m60.1m

PP&E

5.3m5.2m5.4m6.8m7.0m7.0m8.2m8.2m8.3m
Annual
USDFY, 2015FY, 2016

Net Income

(30.8m)(83.3m)

Inventories

2.5m(3.2m)

Accounts Payable

4.8m3.0m

Cash From Operating Activities

(70.6m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(5.8m)(9.4m)(12.6m)(39.2m)(65.0m)(17.1m)(35.8m)(16.3m)(14.4m)(29.6m)

Inventories

1.7m2.7m19.0k(1.9m)(3.2m)175.0k(313.0k)10.0m(1.7m)(981.0k)

Accounts Payable

1.3m2.4m(1.4m)(1.5m)3.0m(1.3m)180.0k10.7m(1.2m)(5.4m)

Cash From Operating Activities

(13.0m)(31.7m)(50.8m)(15.9m)(22.3m)(12.7m)(21.2m)
USDY, 2018

EV/EBIT

-6.3 x

EV/CFO

-7.6 x

EV/FCF

-7.3 x

Financial Leverage

-4.5 x
Show all financial metrics
Report incorrect company information

Neos Therapeutics News and Updates

Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)

Approximately 1.4 Million Patients in the U.S. with Neurological Diseases Battle Sialorrhea with Burdensome and Complex Treatment Options

Neos Therapeutics Reports Second Quarter 2018 Financial Results

Company to host conference call today at 8:30am ET Company to host conference call today at 8:30am ET

Neos Therapeutics to Host Second Quarter 2018 Financial Results Conference Call on August 8, 2018

DALLAS and FORT WORTH, Texas, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, toda…
Report incorrect company information

Neos Therapeutics Company Life and Culture

Report incorrect company information